Company Filing History:
Years Active: 2024
Title: **Inventor Spotlight: Nataly Manjarrez Orduño in Princeton, NJ**
Introduction
Nataly Manjarrez Orduño is an innovative inventor based in Princeton, NJ, recognized for her significant contributions to the field of cancer research. With a focus on developing predictive biomarkers, Nataly's work aims to enhance the efficacy of cancer treatments, particularly in relation to checkpoint inhibitors.
Latest Patents
One of Nataly's notable patents is titled "Predictive peripheral blood biomarker for checkpoint inhibitors." This groundbreaking patent presents the discovery that the ratio of circulating central memory T cells to effector T cells in cancer patients can predict the inflammatory status of a tumor. This findings have important implications for treatment, as tumors with an inflammatory milieu are known to have better responses to checkpoint inhibitors, such as PD-1 antagonists. Her innovative assay utilizes peripheral blood samples to predict patient responsiveness to therapies targeting the PD-1 receptor and its ligand, PD-L1.
Career Highlights
Nataly is currently a key member of Bristol-Myers Squibb Company, where her research efforts are crucial in advancing cancer treatment options. Her dedication to the field and the development of predictive assays underscores her commitment to improving patient outcomes.
Collaborations
Throughout her career, Nataly has collaborated with talented professionals, including her coworker Suzanne J. Suchard. Working alongside such esteemed colleagues, she has furthered her research and contributed to the development of innovative cancer therapies that utilize biomarkers for enhanced treatment precision.
Conclusion
In conclusion, Nataly Manjarrez Orduño's work exemplifies the power of innovation in the medical field. Her patent not only showcases her expertise in cancer research but also highlights the potential for predictive biomarkers to revolutionize patient care in oncology. As she continues her work at Bristol-Myers Squibb, the medical community eagerly anticipates the impact of her research on future cancer treatments.